Abstracts Archive - Page 124 of 2425 - ACR Meeting Abstracts

Abstract Number: 1660 • ACR Convergence 2024
Systemic Inflammation and Transcriptional Reprogramming Contribute to Progression to Active Rheumatoid Arthritis in ACPA+ Individuals
Mark Gillespie¹, Ziyuan He¹, Adam Savage¹, Pravina Venkatesan¹, Marla Glass¹, Lauren Okada², Nhung Tran², Yudong He², Samir Rachid Zaim¹, Padmapriyadarshini Ravisankar², Christy Bennett¹, Julian Reading², Jessica Garber², Palak Genge², Veronica Hernandez², Alexander Heubeck², Erin Kawelo², Upaasana Krishnan², Kevin Lee², Regina Mettey², Blessing Musgrove², Vaishnavi Parthasarathy², Cole Phalen², Charles Roll², Tyanna Stuckey², Morgan Weiss¹, Claire Gustafson², Qiuyu Gong², Emma Kuan², Tao Peng², Lucas Graybuck², Kristen Demoruelle³, Kristine Kuhn⁴, David Boyle⁵, Fan Zhang⁴, Thomas Bumol⁶, Ananda Goldrath², Xiaojun Li¹, V. Michael Holers⁷, Peter Skene¹, Gary Firestein⁸, Kevin Deane⁹ and Troy Torgerson¹⁰, ¹Allen Institute for Immunology, Seattle, WA, ²Allen Institute for Immunology, Seattle, ³University of Colorado Anschutz Medical Campus, Golden, CO, ⁴University of Colorado, Aurora, CO, ⁵UCSD, La Jolla, CA, ⁶Allen Institute for Immunology, San Diego, CA, ⁷University of Colorado, Denver, CO, ⁸University of California, San Diego, San Diego, CA, ⁹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹⁰Allen Institute for Immunology, Enumclaw, WA
Background/Purpose: Elevated levels of RA-associated autoantibodies (ACPA, RF) prior to the clinical onset of inflammatory arthritis (IA) define a state of risk for future development…
Abstract Number: 1682 • ACR Convergence 2024
Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor
Eric Hanson¹, Daniel Dairaghi¹, Andrew C. Vendel¹, Jonathan Sims¹, Yasushi Takita¹, Lucy Yan², Andrew Chow², Simon Shaw² and esteban S. Masuda², ¹Eli Lilly and Company, Indianapolis, IN, ²Rigel Pharmaceuticals, San Francisco
Background/Purpose: Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors are under investigation in chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Ocadusertib (LY3871801;…
Abstract Number: 1695 • ACR Convergence 2024
Efficacy of Upadacitinib in Patients with Giant Cell Arteritis: Subgroup Analysis of the SELECT-GCA Phase 3 Trial
Peter Merkel¹, Arathi Setty², Ricardo Blanco-Alonso³, Ravi Suppiah⁴, Thomas Daikeler⁵, Valerie Devauchelle⁶, Elisabeth Brouwer⁷, Hiromichi Tamaki⁸, Liu Meng², Yang Yang², Avani Joshi², Charles Phillips², Peter K. Wung² and Cristina Ponte⁹, ¹Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²AbbVie, North Chicago, IL, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁴Health New Zealand, Te Toka Tumai Auckland, Auckland, New Zealand, ⁵university hospital, Basel, Switzerland, ⁶UBO, Brest, France, ⁷University Medical Center Groningen, Groningen, Netherlands, ⁸St. Luke's International Hospital, Tokyo, Japan, ⁹Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal., Lisbon, Portugal
Background/Purpose: Giant cell arteritis (GCA) is a chronic systemic vasculitis with limited targeted therapeutic options. The recent SELECT-GCA phase 3 trial demonstrated a favorable benefit-risk…
Abstract Number: 1728 • ACR Convergence 2024
Higher Oral Steroid Dose Is Associated with Worse Survival in Immune Checkpoint Inhibitor-Treated Rheumatoid Arthritis Patients with Metastatic Non-Small Cell Lung Cancer
Deanna Jannat-Khah¹, Jeffrey Curtis², Fenglong Xie³, Ashish Saxena⁴ and Anne Bass⁵, ¹Hospital For Special Surgery, New York, NY, ²The University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: It is unknown if steroid use for RA patients could interfere with the benefits of immune checkpoint inhibitors (ICI) as cancer therapies. Additionally, it…
Abstract Number: 1640 • ACR Convergence 2024
ACR/EULAR 2022 Classification Criteria Compared to the ACR 1990 Classification Criteria in the ARTESER Registry of Giant Cell Arteritis
Eugenio De Miguel¹, Iñigo Hernández-Rodríguez², Maite Silva-Diaz³, Joaquin María Belzunegui:⁴, Patricia Moya⁵, Marina Tortosa-Cabañas⁶, Vanessa Andrea Navarro⁷, Joan Calvet⁸, Ivette Casafont-Solé⁹, Jose A Román-Ivorra¹⁰, Selene Labrada-Arrabal¹¹, Margarida Vasques Rocha:¹², Carlota L Iñiguez:¹³, Vanesa Hernández-Hernández¹⁴, Cristina Campos-Fernández¹⁵, María Alcalde Villar:¹⁶, Antonio Juan-Mas¹⁷, Francisco-Javier Prado-Galbarro¹⁸, Itziar Calvo¹⁹, Julio Sánchez-Martín²⁰, Javier Narvaez-García²¹ and Ricardo Blanco-Alonso²², and ARTESER Project Collaborative Group, ¹Hospital Universitario La Paz, Madrid, Spain, ²Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ³Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁴H de Donostia, Donostia-San Sebasti, Spain, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁶Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁷Hospital Moisès Broggi, Sant Joan Despí, Spain, ⁸Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA) (UAB), 08208 Sabadell, Spain, Barcelona, Spain, ⁹Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, Barcelona, Spain, ¹⁰Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain, ¹¹Hospital del Mar, Barcelona, Spain, ¹²Hospital Universitario Araba, Vitoria, Spain, ¹³Hospital Universitario Lucus Augusti, Galicia, Spain, Galicia, Spain, ¹⁴Hospital Universitario de Canarias, San Cristobal de La Laguna, Canarias, Spain, ¹⁵Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, ¹⁶Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain, ¹⁷Rheumatology Department, Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Cantabria, Spain, ¹⁸Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana-Unidad Xochimilco,, Mexico, Mexico, ¹⁹Hospital Universitario de Basurto, Bilbao, Spain, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: The diagnosis of giant cell arteritis (GCA) has been guided for years by the ACR 1990 classification criteria but the emergence of the image…
Abstract Number: 1574 • ACR Convergence 2024
Therapeutic Strategy in Patients with Mixed Connective Tissue Disease: A Multicenter Retrospective Study in the French MCTD Cohort
Kevin Chevalier¹, Benjamin Thoreau², Marc Michel³, Bertrand Godeau⁴, Christian AGARD⁵, Thomas Papo⁶, Karim Sacré⁶, Raphaele Seror⁷, Xavier Mariette⁸, Patrice Cacoub⁹, Ygal Benhamou¹⁰, Hervé Levesque¹⁰, Cécile Goujard¹¹, Olivier Lambotte¹¹, Bernard Bonnotte¹², Maxime SAMSON¹³, Felix Ackermann¹⁴, Jean Schmidt¹⁵, Pierre Duhaut¹⁶, Jean-Emmanuel Kahn¹⁷, Thomas Hanslik¹⁷, Nathalie Costedoat-chalumeau¹⁸, Benjamin Terrier¹⁹, Alexis Régent²⁰, bertrand Dunogue², Pascal cohen²¹, Veronique LE GUERN²², Eric Hachulla²³, Luc Mouthon² and Benjamin Chaigne²⁴, ¹Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France, Paris, France, ²Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ³2. Department of Internal Medicine, Henri-Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil (UPEC), Créteil, France., Créteil, France, ⁴Department of Internal Medicine, Henri-Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil (UPEC), Créteil, France., Créteil, France, ⁵Nantes University Hospital, Nantes, France, ⁶Université Paris Cité, Paris, France, ⁷Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ⁸Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ⁹Sorbonne Université, Paris, ¹⁰Department of Internal Medicine, CHU de Rouen, UniRouen, Rouen, France., Rouen, France, ¹¹Université Paris Saclay, Department of Internal Medicine and clinical immunology, Bicêtre hospital, Assistance Publique-Hôpitaux de Paris, UMR1184 Inserm, CEA, Le Kremlin Bicêtre, France, Kremlin-Bicêtre, France, ¹²Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France., Dijon, France, ¹³Dijon University Hospital, Dijon, France, ¹⁴Department of Internal Medicine, Foch Hospital, Suresnes, France., Suresnes, France, ¹⁵Department of Internal Medicine and RECIF, Amiens University Hospital, Université Picardie Jules Verne, Amiens, France., Amiens, France, ¹⁶Department of Internal Medicine and RECIF, Amiens-Picardie University Hospital, AMIENS, France, ¹⁷Department of Internal Medicine, Ambroise Paré Hospital, Assistance Publique - Hôpitaux de Paris, Université de Versailles Saint-Quentin-en-Yvelines, Boulogne-Billancourt, France, Boulogne Billancourt, France, ¹⁸University Paris Cité, Paris, France, ¹⁹Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ²⁰National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ²¹National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ²²Cochin hospital, Paris, France, ²³Department of Internal Medicine and clinical immunology, North-West National Reference Center for Rare Systemic Autoimmune Diseases iques et Auto-Immunes Rares du Nord-Ouest, Hôpital Claude Huriez, Université de Lille, France, Lille, France, ²⁴Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France
Background/Purpose: Mixed connective tissue disease (MCTD) is a rare systemic disorder that belongs to connective tissue diseases (CTD). Few studies are available on MCTD treatment.…
Abstract Number: 1588 • ACR Convergence 2024
Validation of a Lung Ultrasound Interpretation Criteria for Interstitial Lung Disease Screening in Systemic Sclerosis and Inflammatory Myopathy
Robert Fairchild¹, Diane Mar², Mariani Deluna³, Henry Guo³, David Fiorentino⁴ and Lorinda Chung⁵, ¹Stanford University, San Francisco, CA, ²VA Palo Alto / Stanford, Palo Alto, CA, ³Stanford University, Palo Alto, CA, ⁴Stanford University, Menlo Park, CA, ⁵Stanford University, Woodside, CA
Background/Purpose: Interstitial lung disease (ILD) is a common complication of connective tissue disease (CTD) with a high prevalence in SSc and inflammatory myopathy (IM). Early…
Abstract Number: 1697 • ACR Convergence 2024
Results of a One Year Randomized Double-Blind Placebo-Controlled Trial with Methotrexate 25mg Per Week for Recently Diagnosed PolyMyalgia Rheumatica
Thomas Bolhuis¹, Noortje Kooijman¹, Diane Marsman¹, Gijs Snijders², Alfons den Broeder³, Nathan den Broeder⁴ and Aatke Van der maas⁵, ¹Department of Rheumatology, Sint Maartenskliniek, Ubbergen, The Netherlands, Ubbergen, Netherlands, ²Department of Rheumatology, Gelre Ziekenhuizen, Apeldoorn, The Netherlands, Gelre, Netherlands, ³Sint Maartenskliniek, Ubbergen, Netherlands, ⁴Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ⁵St Maartenskliniek, Ubbergen, Netherlands
Background/Purpose: The most effective treatment for Polymyalgia rheumatica (PMR) are glucocorticoids (GC), but these are associated with toxicity. Three randomized controlled trials (RCTs) suggest methotrexate…
Abstract Number: 1704 • ACR Convergence 2024
Cluster Analysis of Peripheral Blood Mononuclear Cell Subpopulations Using Deep Immunophenotyping, Multiplex Serum Cytokines and Small Lipid Mediators at the Very Early Stages of Steroid Treatment in Polymyalgia Rheumatica and Giant Cell Arteritis
Dimitrios Anastasios Palamidas¹, Maria Papadaki², Nikolaos Paschalidis³, Eleftherios Pavlos⁴, Loukas chatzis¹, Ourania Argyropoulou⁵, Panagiota Palla⁵, Ioanna-Evdokia Galani⁶, Andreas Goules⁷, Evangelos Andreakos⁴ and Athanasios Tzioufas⁸, ¹Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, ²Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Cholargos Athens, Attiki, Greece, ³Mass Cytometry-CyTOF Laboratory, Center for Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece, Cholargos Athens, Greece, ⁴Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Athens, Greece, ⁵Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Athens, Greece, ⁶Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Cholargos Athens, Greece, ⁷GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, ⁸LAIKO HOSPITAL, Athens, Greece
Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are autoimmune/autoinflammatory disorders affecting patients over 50 years and are characterized by an acute inflammatory response.…
Abstract Number: 1737 • ACR Convergence 2024
RheumMadness 2024: The Practical Impact of the Practically Perfect Season
Eric Wilson¹, Benjamin Lueck², Sabahat Usmani³, Laura Arneson⁴, Meredith Balbach⁵, Lauren Phillips⁶, John Kellogg², Courtney Bair⁷, Michael Macklin⁸, Iman Qaiser⁹, Amanda Rodriguez¹⁰, Akrithi Garren¹¹, Nina Couette¹², Melissa Briones¹³, Matthew Sparks⁷, Lisa Criscione-Schreiber², Guy Katz¹⁴ and David Leverenz⁷, ¹Duke University Hospital, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³WEISS Memorial Hospital, Chicago, IL, ⁴Northwestern University, Chicago, IL, ⁵Vanderbilt University, Nashville, TN, ⁶University of Michigan, Ann Arbor, MI, ⁷Duke University, Durham, NC, ⁸University of Chicago, Chicago, IL, ⁹Choctaw Nation of Oklahoma Health Services Authority, McKinney, TX, ¹⁰Lankenau Medical Center, Philadelphia, PA, ¹¹MedStar/Georgetown Washington Hospital Center, Silver Spring, MD, ¹²Genesis Healthcare System, Columbus, OH, ¹³Loyola University, Maywood, IL, ¹⁴Massachusetts General Hospital, Boston, MA
Background/Purpose: RheumMadness is an online tournament of competing rheumatology concepts. The 2024 season focused on the practical impact of published manuscripts; to mirror this, we…
Abstract Number: 1703 • ACR Convergence 2024
Single Cell and Spatial Transcriptomics Implicate Vascular Cell Orchestration of Inflammatory Changes After Ultraviolet Light Exposure
Rachael Wasikowski¹, Erin Theisen², Jie An³, Lam C. Tsoi¹, Ksenia Anufrieva⁴, Kevin Wei⁵, Johann Gudjonsson⁶ and Keith Elkon³, ¹Michigan, Dept. of Dermatology, Ann Arbor, MI, ²Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³University of Washington, Seattle, WA, ⁴BWH, Cambridge, MA, ⁵Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁶University of Michigan, Ann Arbor, MI
Background/Purpose: Skin sensitivity to sunlight affects ~70% of systemic lupus erythematosus (SLE). In addition, ultraviolet radiation (UVR) can stimulate systemic disease flares, but how this…
Abstract Number: 1684 • ACR Convergence 2024
Autoantibodies to Transcription Factor a Mitochondria Are Associated with Damage Accrual, Malignancy Risk and Mortality in SLE
Eduardo Gomez¹, Daniel Goldman², Merlin Paz³, Michelle Petri² and Felipe Andrade⁴, ¹The Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³Johns Hopkins Medicine, Baltimore, MD, ⁴The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: We recently identified autoantibodies in SLE that target transcription factor A mitochondrial (TFAM), a critical protein in mitochondrial DNA transcription and packaging1. These autoantibodies…
Abstract Number: 1743 • ACR Convergence 2024
What Are the Benefits of Treating Rheumatoid Arthritis Patients to Remission After Achieving Low Disease Activity in Clinical Practice?
Jing Zhao¹, Urbano Sbarigia², Jackie Kwong¹, Chinmayi Naik³, Federico Zazzetti⁴, Nancy Shadick³ and Michael Weinblatt⁵, ¹Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, ²Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³Brigham and Women’s Hospital, Boston, MA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend low disease activity (LDA) as initial treatment goal with remission as a subsequent target whenever possible.…
Abstract Number: 1647 • ACR Convergence 2024
Improved Fertility in Women with Rheumatoid Arthritis and a Wish to Conceive When Treated According to a Treat-to-target Approach Aimed at Remission
Cornelia H. Quaack¹, Esther Röder¹, Hetty M. Wintjes¹, Anneke J. van Steensel-Boon¹, Annemarie G.M.G.J. Mulders², Laura C.J. Kranenburg-van Koppen¹ and radboud J.e.m. Dolhain¹, ¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Obstetrics and Gynaecology, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Time to conception, known as time to pregnancy (TTP), is prolonged in women diagnosed with RA. High rates of infertility, defined as the inability…
Abstract Number: 1723 • ACR Convergence 2024
Clustering Analysis with Unsupervised Machine Learning Process to Phenotype the Cardiovascular Risk of Patients with Rheumatoid Arthritis Beyond the 10-year Prediction Algorithm
Fabio Cacciapaglia¹, Vincenzo Venerito², Gian Luca Erre³, Matteo Piga⁴, Andreina Manfredi⁵, Garifallia Sakellariou⁶, Ombretta Viapiana⁷, Elisa Gremese⁸, Elena Bartoloni Bocci⁹, Francesca Romana Spinelli¹⁰ and Fabiola Atzeni¹¹, and "Cardiovascular Obesity and Rheumatic DISeases" Study Group of the Italian Society of Rheumatology, ¹Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ²Rheumatology Unit, DiMePRe-J University of Bari, Bari, Italy, ³Rheumatology Unit - University of Sassari, Sassari, Italy, ⁴Rheumatology Unit - University of Cagliari, Cagliari, Italy, ⁵University of Modena and Reggio Emilia, Modena, ⁶Department of Internal Medicine and Medical Therapy, University of Pavia, and Istituti Clinici Scientifici Maugeri IRCCS Pavia,, Pavia, Italy, ⁷Rheumatology Unit, University of Verona, Verona, Italy, ⁸Catholic University of the Sacred Heart, Rome, Rome, Italy, ⁹Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, ¹⁰Sapienza University of Rome, Rome - Italy, Roma, Rome, Italy, ¹¹University of Messina, Italy, Messina, Italy
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased cardiovascular (CV) risk, but traditional CV risk factors and available 10-year CV risk estimation models may not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].